Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study

Authors
Category Primary study
JournalTransl. Lung Cancer Res.
Year 2026
This article has no abstract
Epistemonikos ID: a444998b746260fac1002c9effa825a3a4aa7b75
First added on: Oct 10, 2026